A Single-center Study To Evaluate The Safety and Efficacy of Sofosbuvir Plus Ribavirin In Patients With Severe Hepatitis C Recurrence After Liver Transplantation.

Trial Profile

A Single-center Study To Evaluate The Safety and Efficacy of Sofosbuvir Plus Ribavirin In Patients With Severe Hepatitis C Recurrence After Liver Transplantation.

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs Ribavirin (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms ITACOPS
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 16 Sep 2015 Interim results (n = 116) presented at the 17th Congress of the European Society for Organ Transplantation.
    • 12 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top